ABSTRACT
Typhoid fever remains a significant burden in low- and middle-income countries (LMICs). The World Health Organization recommends incorporating typhoid conjugate vaccines (TCVs) into the routine immunization programs of typhoid-endemic countries. Although TCV has been shown to be safe, well tolerated, and effective, evidence on its delivery costs in African settings remains limited. This study provides economic evidence on the cost of implementing TCV catch-up campaigns.
This retrospective provider-perspective costing study evaluated TCV catch-up vaccination campaigns conducted in the Asante-Akim North District of Ghana and the Kisantu Health Zone of the Democratic Republic of the Congo (DRC). The campaigns targeted children aged 9 months to 15 years. An incremental costing approach was used, and a Microsoft Excel-based tool was developed to estimate costs.
The total number of vaccinated individuals was 54,814; 10,052 in Ghana and 44,762 in the DRC. The financial cost per fully immunized person (FIP), including vaccine and vaccination supply costs, was estimated at US$ 5.78 in Ghana and US$ 5.47 in the DRC. The corresponding economic costs were estimated at US$ 6.09 in Ghana and US$ 5.89 in the DRC. Vaccine procurement and vaccination supplies represented the largest cost component, accounting for US$ 2.76 per FIP in Ghana and US$ 2.39 per FIP in the DRC, followed by service delivery and service delivery support activities.
This study provides empirical estimates of the financial and economic costs of TCV catch-up campaigns in Ghana and the DRC. These findings provide country-specific evidence to inform planning, budgeting, economic evaluation, and policy decisions regarding future TCV introduction in typhoid-endemic settings.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The delivery cost estimation of TCV in both countries presented here is part of research protocols Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) and An open-label effectiveness study of a typhoid conjugate vaccine in Kisantu, Democratic Republic of the Congo (TyVECO). These studies were approved by the Institutional Review Board (IRB) of the International Vaccine Institute (IVI), as well as by the Ghana Health Service Ethics Review Committee, the Committee on Human Research, Publications and Ethics of Kwame Nkrumah University of Science and Technology (CHRPE-KNUST), and the Ghana Food and Drugs Authority (FDA) in Ghana, and the Ethics Committee of the School of Public Health at the University of Kinshasa in the DRC.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* These authors share first authorship
The Funding Information has been revised to list the European & Developing Countries Clinical Trials Partnership and the Bill & Melinda Gates Foundation as separate funding sources. The Distribution/Reuse Option has been changed to CC BY.
Data Availability
Aggregated data may be made available by the corresponding author upon reasonable request and subject to the conditions of the ethical approval.
Funder Information Declared
